Embolization of the middle meningeal artery for treating chronic subdural hematomas
Official title: Middle Meningeal Artery (MMA) Embolization for cSDH: Rationale and Design for the STOp Recurrence of MMA Bleeding (STORMM) Randomized-Control Trial
Run by University Hospital, Geneva · NCT06163547 · Data updated 2026-11-12
This study is testing if blocking a specific artery can help people with chronic subdural hematomas either when combined with surgery or as a standalone treatment for those who can’t have surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | University Hospital, Geneva Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Geneva and 1 other locations) |
| Status | Recruiting |
| Started | February 18, 2025 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2027 |
| Registry record updated | March 17, 2026 |
| Trial ID | NCT06163547 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18-100 with symptomatic chronic subdural hematomas located at the convexities.
✕Probably not a fit
Patients who may not benefit include those who cannot provide consent, are pregnant, or have contraindications for angiography.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the efficacy of middle meningeal artery (MMA) embolization in patients with chronic subdural hematomas (cSDH). It aims to evaluate the recurrence rates of cSDH after combined surgical and MMA embolization treatments compared to surgery alone. Additionally, the study assesses the effectiveness of MMA embolization as a standalone treatment for patients who cannot undergo surgery. The research involves a multicenter randomized control trial to provide higher-level evidence regarding the safety and efficacy of this intervention.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the recurrence rates of chronic subdural hematomas, potentially improving patient outcomes and reducing the need for additional surgeries.
How similar studies have gone: While there is limited evidence supporting the efficacy of MMA embolization, previous case series suggest lower recurrence rates, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18-100 * Consent possible * cSDH located at the convexities * Patients with symptomatic cSDH * Patients with asymptomatic large chronic/subacute hematoma after 6 weeks of failed conservative treatment Exclusion Criteria: * Consent not possible * Pregnancy * Prisoner * Angiography contraindication * Patient for whom follow-up is problematic (e.g. distant residency, homeless …) * Previous surgery for cSDH
Where it's running
-
Geneva University Hospitals
Geneva, Switzerland Recruiting -
Eoc
Lugano, Switzerland Recruiting
Study contacts
- Principal investigator: Aria Nouri — University Hospital, Geneva
- Study coordinator: Aria Nouri
- Email: aria.nouri@hug.ch
- Phone: +41795530958
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Seeing if antibiotics given after surgery reduce recurrence of chronic subdural hematoma
This trial will test whether a short course of amoxicillin‑clavulanate given after surgery can lower the chance of chronic subdural hematoma coming back in adults.
-
Middle Meningeal Artery Coagulation During Burr-Hole Drainage for Chronic Subdural Haematoma
This study tests whether safely coagulating small branches of the middle meningeal artery during burr-hole drainage can reduce recurrence of chronic subdural haematoma in adults receiving standard surgical care.
-
Enhanced recovery pathway for burr-hole drainage in chronic subdural hematoma patients
This project tests whether an enhanced recovery protocol for adults having burr-hole drainage for chronic subdural hematoma can reduce recurrence and complications compared with past patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.